A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

被引：0
|
作者：
Jordan D. Berlin
Dona B. Alberti
Rhoda Z. Arzoomanian
Chris A. Feierabend
Kris J. Simon
Kim A. Binger
Rebecca M. Marnocha
George Wilding
机构：
[1] University of Wisconsin,Division of Oncology
来源：
Investigational New Drugs | 1998年 / 16卷
关键词：
gemcitabine; 5-fluorouracil; leucovorin; phase I study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: This was a dose escalation phase I trial designed to establish the MTD (maximum tolerated dose) and toxicity profile of the combination of gemcitabine, leucovorin and 5-fluorouracil (5-FU).
引用
收藏
页码：325 / 330
页数：5
相关论文
共 50 条
  • [1] A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and or metastatic solid tumors
    Berlin, JD
    Alberti, DB
    Arzoomanian, RZ
    Feierabend, CA
    Simon, KJ
    Binger, KA
    Marnocha, RM
    Wilding, G
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 325 - 330
  • [2] Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
    Poplin, E
    Roberts, J
    Tombs, M
    Grant, S
    Rubin, E
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 57 - 62
  • [3] Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
    Elizabeth Poplin
    John Roberts
    Marybeth Tombs
    Steven Grant
    Eric Rubin
    Investigational New Drugs, 1999, 17 : 57 - 61
  • [4] Phase I Trial of Sorafenib in Combination With 5-Fluorouracil/Leucovorin in Advanced Solid Tumors
    Shacham-Shmueli, Einat
    Geva, Ravit
    Figer, Arie
    Bulocinic, Sarah
    Nalbandyan, Karen
    Shpigel, Shulim
    Atsmon, Jacob
    Brendel, Erich
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 656 - 669
  • [5] Phase i study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas
    Olszewski A.J.
    Grossbard M.L.
    Chung M.S.
    Chalasani S.B.
    Malamud S.
    Mirzoyev T.
    Kozuch P.S.
    Journal of Gastrointestinal Cancer, 2013, 44 (2) : 182 - 189
  • [6] A phase I study of NK012 in combination with 5-fluorouracil with or without leucovorin in patients (pts) with advanced solid tumors
    Jones, Suzanne Fields
    Burris, Howard A.
    Infante, Jeffrey R.
    Greco, Frank A.
    Spigel, David R.
    Kawamura, Shigeyuki
    Ishioka, Tatsunari
    Yamazaki, Hiroko
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
    Cho, CD
    Fisher, GA
    Halsey, J
    Sikic, BI
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (02) : 117 - 123
  • [8] Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
    Cheryl D. Cho
    George A. Fisher
    Joanne Halsey
    Branimir I. Sikic
    Investigational New Drugs, 2006, 24 : 117 - 123
  • [9] A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors
    Saif, Muhammad Wasif
    Sellers, Sandra
    Diasio, Robert B.
    Douillard, Jean-Yves
    ANTI-CANCER DRUGS, 2010, 21 (07) : 716 - 723
  • [10] Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2)
    André, T
    Noirclerc, M
    Hammel, P
    Meckenstock, R
    Landi, B
    Cattan, S
    Selle, F
    Codoul, JF
    Guerrier-Parmentier, B
    Mokhtar, R
    Louvet, C
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (8-9): : 645 - 650
12345